Cancer Urology

Онкоурология

1726-97761996-1812

Publishing House ABV Press

1108

10.17650/1726-9776-2008-4-2-73-77

REVIEW

ОБЗОР

Drug prophylaxis of the prostate cancer. Long term results analysis

Медикаментозная профилактика рака предстательной железы. Исследование PCPT. Анализ отдаленных результатов

Pushkar

D. U.

Пушкарь

Д. Ю.

Russian Federation

Rasner

P. I.

Раснер

П. И.

Russian Federation

Кафедра урологии МГМСУ

30062008

73771502202015022020

https://oncourology.abvpress.ru/oncur/article/view/1108

1. Klein E.A., Thompson I.M., Klein E.A. et al. Update on chemoprevention of prostate cancer. Curr Opin Urol 2004;14:143—9.

Klein E.A., Thompson I.M., Klein E.A. et al. Update on chemoprevention of prostate cancer. Curr Opin Urol 2004;14:143—9.

2. Isaacs J.T. Control of cell proliferation and cell death in the normal and neoplastic prostate: a stem cell model. In: C.H. Rodgers, D.S. Coffy, G.R. Cunha et al. (eds) Benign prostatic hyperplasia II. NIH Publ. No 87—2881, US dept. Health, Human Serv. Bethesda: NIH; 1987. p. 85—94.

Isaacs J.T. Control of cell proliferation and cell death in the normal and neoplastic prostate: a stem cell model. In: C.H. Rodgers, D.S. Coffy, G.R. Cunha et al. (eds) Benign prostatic hyperplasia II. NIH Publ. No 87—2881, US dept. Health, Human Serv. Bethesda: NIH; 1987. p. 85—94.

3. Cabot A. The question of castration for enlarged prostate. Ann Serg 1896;24:256.

Cabot A. The question of castration for enlarged prostate. Ann Serg 1896;24:256.

4. Huggins C., Hodges C.V. Studies of prostate cancer: I. The effect of castration on advanced carcinoma of the prostate gland. Arh Surg 1941;43:209.

Huggins C., Hodges C.V. Studies of prostate cancer: I. The effect of castration on advanced carcinoma of the prostate gland. Arh Surg 1941;43:209.

5. Сивков А.В., Ощепков В.Н. Фармакотерапия доброкачественной гиперплазии и рака предстательной железы. Финастерид: 20 лет клинической практики лечения больных аденомой предстательной железы. Consilium Medicum 2006;08(4):36–9.

Сивков А.В., Ощепков В.Н. Фармакотерапия доброкачественной гиперплазии и рака предстательной железы. Финастерид: 20 лет клинической практики лечения больных аденомой предстательной железы. Consilium Medicum 2006;08(4):36–9.

6. Gormely G.J., Brawley O., Thompson I. The potential application of finasteride for chemoprevention of prostate cancer. Ann N Y Acad Sci 1995;768:163.

Gormely G.J., Brawley O., Thompson I. The potential application of finasteride for chemoprevention of prostate cancer. Ann N Y Acad Sci 1995;768:163.

7. Thompson I.M., Goodman P.J., Tangen C.M. et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349(3):215—24.

Thompson I.M., Goodman P.J., Tangen C.M. et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349(3):215—24.

8. Gormley G.J., Stoner E., Bruskewitz R.C. et al. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N Engl J Med 1992;327(17):1185—91.

Gormley G.J., Stoner E., Bruskewitz R.C. et al. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N Engl J Med 1992;327(17):1185—91.

9. Etzioni R.D., Howlader N., Shaw P.A. et al. Long-term effects of finasteride on prostate specific antigen levels: results from the prostate cancer prevention trial. J Urol 2005;174(3):877—81.

Etzioni R.D., Howlader N., Shaw P.A. et al. Long-term effects of finasteride on prostate specific antigen levels: results from the prostate cancer prevention trial. J Urol 2005;174(3):877—81.

10.

10. Thompson I.M., Tangen C.M., Goodman P.J. et al. Erectile dysfunction and subsequent cardiovascular disease. JAMA 2005;294:2996—3002.

Thompson I.M., Tangen C.M., Goodman P.J. et al. Erectile dysfunction and subsequent cardiovascular disease. JAMA 2005;294:2996—3002.

11.

11. Thompson I.M., Pauler D.K., Goodman P.J. et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4,0 ng per milliliter. N Engl J Med 2004;350:2239—46.

Thompson I.M., Pauler D.K., Goodman P.J. et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4,0 ng per milliliter. N Engl J Med 2004;350:2239—46.

12.

12. Carver B.S., Kattan M.W., Scardino P.T. et al. Gleason grade remains an important prognostic predictor in men diagnosed with prostate cancer while on finasteride therapy. BJU Int 2005;95:509—12.

Carver B.S., Kattan M.W., Scardino P.T. et al. Gleason grade remains an important prognostic predictor in men diagnosed with prostate cancer while on finasteride therapy. BJU Int 2005;95:509—12.

13.

13. Civantos F. et al. Finasteride effect on prostatic hyperplasia and prostate cancer. J Urol Pathol 1997;6:1—13.

Civantos F. et al. Finasteride effect on prostatic hyperplasia and prostate cancer. J Urol Pathol 1997;6:1—13.

14.

14. Bostwick D.G. et al. Treatment changes in prostatic hyperplasia and cancer, including androgen deprivation therapy and radiotherapy. Urol Clin North Am 1999;26:465—79.

Bostwick D.G. et al. Treatment changes in prostatic hyperplasia and cancer, including androgen deprivation therapy and radiotherapy. Urol Clin North Am 1999;26:465—79.

15.

15. Yang X.J. et al. Does long-term finasteride therapy affect the histologic features of benign prostate tissue and prostate cancer on needle biopsy? PLESS Study Group. Proscar longterm efficacy and safety study. Urology 1998;53:696—700.

Yang X.J. et al. Does long-term finasteride therapy affect the histologic features of benign prostate tissue and prostate cancer on needle biopsy? PLESS Study Group. Proscar longterm efficacy and safety study. Urology 1998;53:696—700.

16.

16. Rubin M.A., Allory Y., Molinie V. et al. Effects of long-term finasteride treatment on prostate cancer morphology and clinical outcome. Urology 2005;66:930—4.

Rubin M.A., Allory Y., Molinie V. et al. Effects of long-term finasteride treatment on prostate cancer morphology and clinical outcome. Urology 2005;66:930—4.

17.

17. Bautista O.M. et al. Study desine of the medical Therapy of Prostatic Symptoms (MTOPS) trial. Control Clin Trials 2003;24:224.

Bautista O.M. et al. Study desine of the medical Therapy of Prostatic Symptoms (MTOPS) trial. Control Clin Trials 2003;24:224.

18.

18. Andriole G.L., Roehborn C., Schulman C. et al. Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia. Urology 2004;64:537.

Andriole G.L., Roehborn C., Schulman C. et al. Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia. Urology 2004;64:537.

19.

19. Ishikawa S., Soloway M.S., van der Zwaag R. et al. Prognostic factors in survival free of progression after androgen deprivation therapy for treatment of prostate cancer. J Urol 1989;141(5):1139—42.

Ishikawa S., Soloway M.S., van der Zwaag R. et al. Prognostic factors in survival free of progression after androgen deprivation therapy for treatment of prostate cancer. J Urol 1989;141(5):1139—42.

20.

20. Raivio T., Santti H., Schatzl G. et al. Reduced circulating androgen bioactivity in patients with prostate cancer. Prostate 2003;55(3):194—8.

Raivio T., Santti H., Schatzl G. et al. Reduced circulating androgen bioactivity in patients with prostate cancer. Prostate 2003;55(3):194—8.

21.

21. Thompson I.M., Klein E.A., Lippman S.M. et al. Prevention of prostate cancer with finasteride: US/European perspective. Eur Urol 2003;44(6):650—5.

Thompson I.M., Klein E.A., Lippman S.M. et al. Prevention of prostate cancer with finasteride: US/European perspective. Eur Urol 2003;44(6):650—5.

22.

22. Marberger M., Adolfsson J., Borkowski A. et al. The clinical implications of the prostate cancer prevention trial. BJU Int 2003;92(7):667—71.

Marberger M., Adolfsson J., Borkowski A. et al. The clinical implications of the prostate cancer prevention trial. BJU Int 2003;92(7):667—71.

23.

23. Roehrborn C.G. Prevention of prostate cancer with finasteride. N Engl J Med 2003;349:1569—72.

Roehrborn C.G. Prevention of prostate cancer with finasteride. N Engl J Med 2003;349:1569—72.

24.

24. Djavan B., Zlotta A., Schulman C. et al. Chemotherapeutic prevention studies of prostate cancer. J Urol 2004;171(2 Pt 2):S10—3.

Djavan B., Zlotta A., Schulman C. et al. Chemotherapeutic prevention studies of prostate cancer. J Urol 2004;171(2 Pt 2):S10—3.

25.

25. Algaba F., Epstein J.I., Aldape H.C. et al. Workgroup 5: Assessment of prostate carcinoma in core needle biopsy — definition of minimal criteria for the diagnosis of cancer in biopsy material. Cancer 1996;78: 376—81.

Algaba F., Epstein J.I., Aldape H.C. et al. Workgroup 5: Assessment of prostate carcinoma in core needle biopsy — definition of minimal criteria for the diagnosis of cancer in biopsy material. Cancer 1996;78: 376—81.

26.

26. Bostwick D.G., Qian J., Civantos F. et al. Does finasteride alter the pathology of the prostate and cancer grading? Clin Prostate Cancer 2004;2:228—35.

Bostwick D.G., Qian J., Civantos F. et al. Does finasteride alter the pathology of the prostate and cancer grading? Clin Prostate Cancer 2004;2:228—35.

27.

27. Canby-Haginoa E., Hernandezb J., Branda T.C., Thompson I. Looking back at PCPT: looking forward to new paradigms in prostate cancer screening and prevention. Eur Urol 2007;51(1):27—33.

Canby-Haginoa E., Hernandezb J., Branda T.C., Thompson I. Looking back at PCPT: looking forward to new paradigms in prostate cancer screening and prevention. Eur Urol 2007;51(1):27—33.

28.

28. Klein E.A., Thompson I.M., Klein E.A., Thompson I.M. Update on chemoprevention of prostate cancer. Curr Opin Urol 2004;14:143—9.

Klein E.A., Thompson I.M., Klein E.A., Thompson I.M. Update on chemoprevention of prostate cancer. Curr Opin Urol 2004;14:143—9.

29.

29. Gomella L.G. Chemoprevention using dutasteride: the REDUCE trial. Curr Opin Urol 2005;15:29—32.

Gomella L.G. Chemoprevention using dutasteride: the REDUCE trial. Curr Opin Urol 2005;15:29—32.